Is Iovance Biotherapeutics Stock a Good Investment?
Iovance Biotherapeutics Investment Advice | IOVA |
- Examine Iovance Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Iovance Biotherapeutics' leadership team and their track record. Good management can help Iovance Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Iovance Biotherapeutics' business and its evolving consumer preferences.
- Compare Iovance Biotherapeutics' performance and market position to its competitors. Analyze how Iovance Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Iovance Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Iovance Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Iovance Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Iovance Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Iovance Biotherapeutics Stock
Researching Iovance Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 84.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iovance Biotherapeutics recorded a loss per share of 1.28. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 26th of September 2013.
To determine if Iovance Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iovance Biotherapeutics' research are outlined below:
| Iovance Biotherapeutics generated a negative expected return over the last 90 days | |
| Iovance Biotherapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 164.07 M. Net Loss for the year was (372.18 M) with profit before overhead, payroll, taxes, and interest of 40.08 M. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (352.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Is Iovance Biotherapeutics, Inc. The Top Penny Stock That Will Skyrocket |
Iovance Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iovance Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iovance Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Iovance Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Iovance Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-05-09 | 2016-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2014-11-13 | 2014-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2015-05-11 | 2015-03-31 | -0.11 | -0.14 | -0.03 | 27 | ||
2014-08-08 | 2014-06-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2018-03-12 | 2017-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2016-08-08 | 2016-06-30 | -0.19 | -0.23 | -0.04 | 21 | ||
2017-05-01 | 2017-03-31 | -0.28 | -0.33 | -0.05 | 17 | ||
2016-11-04 | 2016-09-30 | -0.22 | -0.17 | 0.05 | 22 |
Iovance Biotherapeutics Target Price Consensus
Iovance target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Iovance Biotherapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Iovance analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Iovance stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Iovance Biotherapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIovance Biotherapeutics Target Price Projection
Iovance Biotherapeutics' current and average target prices are 3.34 and 23.77, respectively. The current price of Iovance Biotherapeutics is the price at which Iovance Biotherapeutics is currently trading. On the other hand, Iovance Biotherapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Iovance Biotherapeutics Market Quote on 26th of March 2025
Target Price
Analyst Consensus On Iovance Biotherapeutics Target Price
Iovance Biotherapeutics Analyst Ratings
Iovance Biotherapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Iovance Biotherapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Iovance Biotherapeutics' financials, market performance, and future outlook by experienced professionals. Iovance Biotherapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Iovance Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iovance Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iovance Biotherapeutics backward and forwards among themselves. Iovance Biotherapeutics' institutional investor refers to the entity that pools money to purchase Iovance Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Artisan Partners Limited Partnership | 2024-12-31 | 4.5 M | Goldman Sachs Group Inc | 2024-12-31 | 4.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 M | Principal Financial Group Inc | 2024-12-31 | 3.6 M | Venbio Select Advisor Llc | 2024-12-31 | 3.5 M | Palo Alto Investors, Llc | 2024-12-31 | 3 M | Balyasny Asset Management Llc | 2024-12-31 | 2.8 M | Ubs Group Ag | 2024-12-31 | 2.7 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 2.7 M | Vanguard Group Inc | 2024-12-31 | 27.5 M | Mhr Fund Management Llc | 2024-12-31 | 24.4 M |
Iovance Biotherapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.19 B.Market Cap |
|
Iovance Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.52) | (0.55) |
Determining Iovance Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Iovance Biotherapeutics is a good buy. For example, gross profit margin measures Iovance Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iovance Biotherapeutics' profitability and make more informed investment decisions.
Iovance Biotherapeutics' Earnings Breakdown by Geography
Please note, the presentation of Iovance Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iovance Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Iovance Biotherapeutics' management manipulating its earnings.
Evaluate Iovance Biotherapeutics' management efficiency
Iovance Biotherapeutics has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5748) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.53. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 476.1 M, whereas Total Current Assets are forecasted to decline to about 235.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.45 | 2.57 | |
| Tangible Book Value Per Share | 1.48 | 1.55 | |
| Enterprise Value Over EBITDA | (5.28) | (5.54) | |
| Price Book Value Ratio | 3.02 | 2.87 | |
| Enterprise Value Multiple | (5.28) | (5.54) | |
| Price Fair Value | 3.02 | 2.87 | |
| Enterprise Value | 1.7 B | 1.8 B |
The leadership approach at Iovance Biotherapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.929 |
Basic technical analysis of Iovance Stock
As of the 26th of March, Iovance Biotherapeutics retains the Standard Deviation of 4.18, market risk adjusted performance of (1.33), and Risk Adjusted Performance of (0.22). Iovance Biotherapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Iovance Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iovance Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iovance Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iovance Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iovance Biotherapeutics' Outstanding Corporate Bonds
Iovance Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iovance Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iovance bonds can be classified according to their maturity, which is the date when Iovance Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Iovance Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Iovance Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | (1.33) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (371.54) | |||
| Standard Deviation | 4.18 | |||
| Variance | 17.5 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (1.14) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.34) | |||
| Maximum Drawdown | 24.66 | |||
| Value At Risk | (7.85) | |||
| Potential Upside | 4.31 | |||
| Skewness | (1.54) | |||
| Kurtosis | 4.6 |
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | (1.33) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (371.54) | |||
| Standard Deviation | 4.18 | |||
| Variance | 17.5 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (1.14) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.34) | |||
| Maximum Drawdown | 24.66 | |||
| Value At Risk | (7.85) | |||
| Potential Upside | 4.31 | |||
| Skewness | (1.54) | |||
| Kurtosis | 4.6 |
Consider Iovance Biotherapeutics' intraday indicators
Iovance Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Iovance Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 3.34 | |||
| Day Typical Price | 3.34 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.14) | |||
| Relative Strength Index | 27.63 |
Iovance Biotherapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 12th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Iovance Stock media impact
Far too much social signal, news, headlines, and media speculation about Iovance Biotherapeutics that are available to investors today. That information is available publicly through Iovance media outlets and privately through word of mouth or via Iovance internal channels. However, regardless of the origin, that massive amount of Iovance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iovance Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iovance Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iovance Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iovance Biotherapeutics alpha.
Iovance Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Iovance Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iovance Biotherapeutics Historical Investor Sentiment
Investor biases related to Iovance Biotherapeutics' public news can be used to forecast risks associated with an investment in Iovance. The trend in average sentiment can be used to explain how an investor holding Iovance can time the market purely based on public headlines and social activities around Iovance Biotherapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Iovance Biotherapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Iovance Biotherapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Iovance Biotherapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Iovance Biotherapeutics.
Iovance Biotherapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Iovance Biotherapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Iovance Biotherapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Iovance Biotherapeutics' options.
Iovance Biotherapeutics Corporate Management
| Friedrich MD | Chief Officer | Profile | |
| Michele PMP | Senior Management | Profile | |
| JeanMarc MBA | Chief Officer | Profile | |
| Sara Pellegrino | Senior Communications | Profile | |
| Madan Jagasia | Ex Affairs | Profile | |
| Tracy Winton | Executive Resources | Profile | |
| Brian MBA | Senior Technology | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 151.892 | Return On Assets | Return On Equity |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Iovance Biotherapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.